Novel therapies are desperately needed for pediatric solid tumors, where more than 30% of patients die from their disease. Immunotherapies offer significant potential to meet this need, but this potential has not yet been realized in children. Immune checkpoint inhibitors (ICIs), a type of immunotherapy, have shown success in many adult cancers but rarely work for children. This is partly because pediatric tumors have fewer mutations than adult tumors.
